Biosimilars | Specialty

The OncLive Biosimilars condition center page is a comprehensive resource for clinical news and expert insights on currently available and investigational biosimilars for reference drugs such as trastuzumab, rituximab, bevacizumab, and more. This page features news articles, interviews in written and video format, and podcasts that focus on updates with biosimilars and ongoing research with these types of agents.

Transparency Vital in the Dawning Age of Biosimilars in Oncology

August 24th 2018

Gary H. Lyman, MD, FASCO, interprets the available information on biosimilars as it relates to the clinical oncology community.

Dr. Denes Discusses Biosimilar Pricing in Oncology

August 23rd 2018

Alex E. Denes, MD, associate professor of medicine, School of Medicine, Oregon Health and Science University, discusses biosimilar pricing in oncology.

Dr. Ellis Considers the Use of Biosimilars in Oncology

August 22nd 2018

Matthew J. Ellis, MD, PhD, professor and director, Lester and Sue Smith Breast Center, associate director of Precision Medicine, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses considerations for the use of biosimilars in oncology.

Esteva Discusses Promise of Trastuzumab Biosimilar Candidate

August 22nd 2018

Francisco J. Esteva, MD, PhD, discusses the journey of CT-P6 and its promise as a potential biosimilar for trastuzumab in the United States.

Real-World Results Back Filgrastim Biosimilar Use for Febrile Neutropenia

August 22nd 2018

Lee Schwartzberg, MD, discusses a retrospective analysis of patients with nonmyeloid cancer who received a filgrastim biosimilar versus the filgrastim biologic and explains how biosimilars have the potential to transform the field of oncology beyond the scope of supportive care.

Dr. Novik on Benefits/Challenges of Implementing Biosimilars

August 21st 2018

Yelena Novik, MD, associate professor, New York University’s Perlmutter Cancer Center, discusses the benefits and challenges of the global implementation of biosimilars.

Dr. Savin on the Challenges of Developing Biosimilar Clinical Trials

August 17th 2018

Michael A. Savin, MD, assistant professor of medicine, School of Medicine, Oregon Health and Science University, discusses the challenges that come with trying to develop a clinical trial for biosimilars.

Dr. Kolberg Discusses Next Steps with ABP 980

August 16th 2018

Hans-Christian Kolberg, MD, head, Department of Obstetrics and Gynecology, Breast Cancer Center, and Gynecologic Cancer Center at Marienhospital Bottrop, Klinik für Gynäkologie und Geburtshilfe, Bottrop, Germany, discusses next steps with the trastuzumab (Herceptin) biosimilar ABP 980.

Dr. Tripathy on the Progression of Biosimilars in Oncology

August 14th 2018

Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the progression of biosimilars in oncology.

Dr. Kalinsky Discusses Biosimilars in Breast Cancer

August 10th 2018

Kevin Kalinsky, MD, MS, assistant professor of medicine, Division of Hematology and Oncology, NewYork-Presbyterian Hospital/Columbia University Medical School, discusses the promise of biosimilars in breast cancer.

Dr. Arun Considers Biosimilars in the Context of Global Cancer Care

August 10th 2018

Banu Arun, MD, professor in the Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses biosimilars in the context of global cancer care.

Dr. Hurvitz on the Impact of Biosimilars

August 7th 2018

Sara A. Hurvitz, MD, director of the Breast Oncology Program, medical director of the Clinical Research Unit, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses the impact of biosimilars in the treatment of patients with breast cancer.

Dr. Ellis on the Entrance of Biosimilars Into the Field of Oncology

August 6th 2018

Matthew J. Ellis, MD, PhD, professor and director, Lester and Sue Smith Breast Center, associate director of precision medicine, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses the entrance of biosimilars into the field of oncology.

Dr. Shafaee on the Value of Biosimilars

August 2nd 2018

Maryam Nemati Shafaee, MD, assistant professor, Duncan Cancer Center, Lester & Sue Smith Breast Cancer, Baylor College of Medicine, discusses the value of biosimilars in oncology.

EU Approves Trastuzumab Biosimilar for HER2+ Breast, Gastric Cancers

August 1st 2018

PF-05280014 (Trazimera), a biosimilar for trastuzumab (Herceptin), has been approved for use in the European Union to treat patients with HER2 overexpressing metastatic or early breast cancer and HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.

Dr. Tripathy on the Importance of Biosimilars in Oncology

July 26th 2018

FDA Approves Second Filgrastim Biosimilar

July 23rd 2018

The FDA approved filgrastim-aafi (Nivestym), a filgrastim (Neupogen) biosimilar, to prevent and treat side effects associated with cancer treatment, including febrile neutropenia and severe neutropenia.

Biosimilar Uptake in Oncology Faces Many Hurdles

July 17th 2018

Carina Dolan, PharmD, BCOP, discusses the factors that impact the successful uptake of biosimilars in the practice of oncology.

Expert Sees Biosimilars as Integral to Expanding Access, Controlling Costs in Oncology

July 17th 2018

Yelena Novik, MD, shares her thoughts on the use of biosimilars in oncology and their potential impact on practice.

Lead Author Reflects on LILAC Study of Trastuzumab Biosimilar ABP 980

July 13th 2018

Hans-Christian Kolberg, MD, discusses ABP 980 and the future of biosimilars in oncology.